Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.475 USD | -1.65% | +2.75% | -12.65% |
Financials (USD)
Sales 2024 * | 1.07M | Sales 2025 * | 200K | Capitalization | 123M |
---|---|---|---|---|---|
Net income 2024 * | -30M | Net income 2025 * | -61M | EV / Sales 2024 * | 8.31 x |
Net cash position 2024 * | 114M | Net cash position 2025 * | 60.6M | EV / Sales 2025 * | 312 x |
P/E ratio 2024 * |
-2.85
x | P/E ratio 2025 * |
-2.32
x | Employees | 37 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.79% |
Latest transcript on Vistagen Therapeutics, Inc.
1 day | -0.44% | ||
1 week | +2.01% | ||
Current month | -5.38% | ||
1 month | -1.72% | ||
3 months | -10.39% | ||
6 months | +37.65% | ||
Current year | -11.09% |
Managers | Title | Age | Since |
---|---|---|---|
Shawn Singh
CEO | Chief Executive Officer | 61 | 99-12-31 |
Cynthia Anderson
DFI | Director of Finance/CFO | 55 | 23-08-20 |
Joshua Prince
COO | Chief Operating Officer | 54 | 21-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jon Saxe
BRD | Director/Board Member | 88 | 00-05-31 |
Jerry Gin
BRD | Director/Board Member | 81 | 16-02-29 |
Shawn Singh
CEO | Chief Executive Officer | 61 | 99-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 17 M€ | +4.99% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 4.46 | -1.98% | 42 515 |
24-05-16 | 4.55 | -0.87% | 116,714 |
24-05-15 | 4.59 | +1.55% | 101,970 |
24-05-14 | 4.52 | -0.22% | 147,669 |
24-05-13 | 4.53 | +3.66% | 69,762 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.09% | 123M | |
+8.29% | 114B | |
+10.21% | 104B | |
+0.09% | 22.28B | |
-11.90% | 22.41B | |
-5.52% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- VTGN Stock